Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation

ESMO 2019

27 Sep - 1 Oct 2019

Published: 28 Sep 2019

Views: 1625

Rating:

Save

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

Prof Isabelle Ray-Coquard presents data from the PAOLA-1/ENGOT-ov25 trial during a press conference at the 2019 ESMO congress.

This was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.

Watch Prof Isabelle Ray-Coquard's interview with ecancer here.

Watch Dr Susana Banerjee's comment here.

Read more about the study here.

Related Videos

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma (A cancer arising from plasma cells)

Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal

Multiple myeloma (A cancer arising from plasma cells) ( Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal )

Gynaecological Cancers

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Gynaecological Cancers ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma...

Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence ( Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA )

More from ecancer